… Current recommendations for atrial fibrillation patients with … K antagonist in atrial fibrillation
patients 12 months after … a valid consideration for atrial fibrillation patients with stable coronary …

… Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines,
causes of anticoagulation … of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065. …

… Oral anticoagulation should be considered for AF patients with 1 additional … patients who
were not receiving oral anticoagulant or antiplatelet agents, there were 12,935 AF male patients …

… vitamin K antagonists (VKAs) from February 2008 for patients on VKA and September 2013
for patients on novel oral anticoagulants. The primary endpoint was the incidence of MACE …

… This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs. warfarin) in
patients with atrial fibrillation (AF) across body mass index (BMI) categories, including ≥40 …

… Stroke prevention with oral anticoagulants (OACs) is the cornerstone for the management
of atrial fibrillation (AF). However, data about the use of OACs among patients ≥90 years of …

… patients with atrial fibrillation are not being treated with warfarin. Between 1989 and 1993
several clinical trials reported that oral anticoagulation … among patients with atrial fibrillation. A …

… vitamin-K–antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured
… -vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A …

… The unadjusted odds ratios for the association of patient factors with use of overall oral
anticoagulation are shown. The number in parentheses represents the rate of OAC use for each …

… on different direct oral anticoagulants (DOACs) in atrial fibrillation (AF) patients with renal …
meta-analysis comparing oral anticoagulants (OACs) in AF patients with renal impairment, …